A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
Zachary T. Freeman(University of Michigan), Charles G. Drake(Columbia University Irving Medical Center), Linda A. Snyder(Ortho Clinical Diagnostics (United States)), Mark Selby(Bristol-Myers Squibb (Germany)), Jingyi Zhai(University of Michigan), Alexander T. Pearson(University of Chicago), Alyza Skaist(Sidney Kimmel Comprehensive Cancer Center), Alan J. Korman(Bristol-Myers Squibb (Germany)), Thomas R. Nirschl(Johns Hopkins University), John Engelhardt(Bristol-Myers Squibb (United States)), Scott A. Tomlins(Stratasys (Israel)), Ruth Y. Lan(Bristol-Myers Squibb (Germany)), Christina M. Kochel(Johns Hopkins University), Robert J. Johnston(Johns Hopkins University), Srinivasan Yegnasubramanian(Johns Hopkins University), Daniel H. Hovelson(Michigan Medicine), Hui Jiang(Army Medical University), Ali Ghasemzadeh(Johns Hopkins University), Anuj Gupta(Johns Hopkins University), Sarah J. Wheelan(Sidney Kimmel Comprehensive Cancer Center)
Cited by 133
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k